Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma ADR (NQ: ASND )

104.90 -0.59 (-0.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 154,804
Open 105.04
Bid (Size) 101.68 (1)
Ask (Size) 108.17 (1)
Prev. Close 105.49
Today's Range 103.33 - 105.72
52wk Range 61.58 - 134.53
Shares Outstanding 57,152,295
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study
The company is testing a drug for children with achondroplasia, a cause of dwarfism. 
Via Investor's Business Daily
Johnson & Johnson: Taking The Bull By The Horns?
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. 
Via MarketBeat
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory

Performance

YTD
-13.10%
-13.10%
1 Month
-8.71%
-8.71%
3 Month
-8.36%
-8.36%
6 Month
+6.34%
+6.34%
1 Year
-8.30%
-8.30%

More News

Read More
Earnings Scheduled For February 16, 2023
Via Benzinga
Analyst Expectations for Ascendis Pharma's Future
Via Benzinga
Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices
Via Talk Markets
Where Ascendis Pharma Stands With Analysts
Via Benzinga
What 9 Analyst Ratings Have To Say About Ascendis Pharma
Via Benzinga
Analyst Ratings for Ascendis Pharma
Via Benzinga
Ascendis Pharma's Program Hits Primary Goal In Children With Short-Limbed Dwarfism
Via Benzinga
Analyst Ratings for Ascendis Pharma
Via Benzinga
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
6 Analysts Have This to Say About Ascendis Pharma
Via Benzinga
Expert Ratings for Ascendis Pharma
Via Benzinga
Expert Ratings for Ascendis Pharma
Via Benzinga
What 14 Analyst Ratings Have To Say About Ascendis Pharma
Via Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022
Via Benzinga
Ascendis Seeks FDA Nod For TransCon PTH In Adults With Hypoparathyroidism
Via Benzinga
Oppenheimer Maintains Outperform Rating for Ascendis Pharma: Here's What You Need To Know
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Via Benzinga
Ascendis Slammed After Growth Hormone Drug Faces An Unexpected Challenge
Via Investor's Business Daily
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
Via Benzinga
BofA Upgrades Ascendis Pharma After Promising TCP Phase 3 Data
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.